Holdenrieder S - Search Results

1

Time courses of HMGB1 and other inflammatory markers after generalized convulsive seizures.

Nass RD, Wagner M, Surges R, Holdenrieder S. Nass RD, et al. Among authors: holdenrieder s. Epilepsy Res. 2020 May;162:106301. doi: 10.1016/j.eplepsyres.2020.106301. Epub 2020 Feb 26. Epilepsy Res. 2020. PMID: 32126476

2

Methodological and preanalytical evaluation of an HMGB1 immunoassay.

Lehner J, Wittwer C, Fersching D, Siegele B, Holdenrieder S, Stoetzer OJ. Lehner J, et al. Among authors: holdenrieder s. Anticancer Res. 2012 May;32(5):2059-62. Anticancer Res. 2012. PMID: 22593488

3

Blood markers of cardiac stress after generalized convulsive seizures.

Nass RD, Motloch LJ, Paar V, Lichtenauer M, Baumann J, Zur B, Hoppe UC, Holdenrieder S, Elger CE, Surges R. Nass RD, et al. Among authors: holdenrieder s. Epilepsia. 2019 Feb;60(2):201-210. doi: 10.1111/epi.14637. Epub 2019 Jan 15. Epilepsia. 2019. PMID: 30645779

4

Acute metabolic effects of tonic-clonic seizures.

Nass RD, Zur B, Elger CE, Holdenrieder S, Surges R. Nass RD, et al. Among authors: holdenrieder s. Epilepsia Open. 2019 Oct 22;4(4):599-608. doi: 10.1002/epi4.12364. eCollection 2019 Dec. Epilepsia Open. 2019. PMID: 31819916 Free PMC article.

5

Fersching DM, Nagel D, Siegele B, Salat C, Heinemann V, Holdenrieder S, Stoetzer OJ. Fersching DM, et al. Among authors: holdenrieder s. Anticancer Res. 2012 May;32(5):2047-58. Anticancer Res. 2012. PMID: 22593487

6

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.

Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S. Kohles N, et al. Among authors: holdenrieder s. Tumour Biol. 2012 Dec;33(6):2401-9. doi: 10.1007/s13277-012-0504-2. Epub 2012 Sep 11. Tumour Biol. 2012. PMID: 22965881

7

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.

Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S. Fahmueller YN, et al. Among authors: holdenrieder s. Int J Cancer. 2013 May 15;132(10):2349-58. doi: 10.1002/ijc.27894. Epub 2013 Jan 18. Int J Cancer. 2013. PMID: 23047645 Free article.

8

Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.

Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S. Wittwer C, et al. Among authors: holdenrieder s. Int J Cancer. 2013 Dec 1;133(11):2619-30. doi: 10.1002/ijc.28294. Epub 2013 Aug 9. Int J Cancer. 2013. PMID: 23729200 Free article.

9

Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter?

Cebrián MJ, Bauden M, Andersson R, Holdenrieder S, Ansari D. Cebrián MJ, et al. Among authors: holdenrieder s. Anticancer Res. 2016 Sep;36(9):4381-9. doi: 10.21873/anticanres.10981. Anticancer Res. 2016. PMID: 27630273 Review.

10

Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients.

Handke NA, Rupp ABA, Trimpop N, von Pawel J, Holdenrieder S. Handke NA, et al. Among authors: holdenrieder s. Diagnostics (Basel). 2021 Feb 20;11(2):356. doi: 10.3390/diagnostics11020356. Diagnostics (Basel). 2021. PMID: 33672622 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

270 results

Search Page